Table III.
Subgroup meta-analysis between OSA and MS
| Subgroup | No. of studies | OR | 95% CI | PZ | I 2 | P H |
|---|---|---|---|---|---|---|
| Study design: | ||||||
| Cross sectional | 8 | 2.18 | 1.35–3.53 | 0.001 | 85% | < 0.001 |
| Case control | 2 | 1.26 | 1.07–1.48 | 0.006 | 0 | 0.61 |
| MS criteria: | ||||||
| NCEP ATPIII | 7 | 1.44 | 1.11–1.88 | 0.006 | 79% | < 0.001 |
| IDF guidelines | 1 | 5.88 | 1.96–16.63 | 0.002 | – | – |
| Japanese criteria | 2 | 2.10 | 1.46–3.02 | < 0.001 | 0 | 0.89 |
| Diagnostic method of OSA: | ||||||
| Standard PSG | 8 | 2.17 | 1.42–3.31 | < 0.001 | 86% | < 0.001 |
| Portable PSG | 2 | 1.21 | 1.01–1.45 | 0.04 | 0 | 0.56 |
OSA – obstructive sleep apnea, MS – metabolic syndrome, PSG – polysomnography, NCEP ATPIII – National Cholesterol Education Program Adult Treatment Panel III, IDF – International Diabetes Federation.